Sarepta Therapeutics Inc. (SRPT)

84.84
2.20 2.50
NASDAQ : Health Technology
Prev Close 87.02
Open 87.41
Day Low/High 83.91 / 88.15
52 Wk Low/High 83.62 / 165.87
Volume 1.55M
Avg Volume 1.69M
Exchange NASDAQ
Shares Outstanding 74.34M
Market Cap 6.54B
EPS -5.50
Div & Yield N.A. (N.A)
Stock Indexes Manage Another Day of Gains

Stock Indexes Manage Another Day of Gains

If you're not nervous, you're not paying attention.

Market Strength Is Putting Bids Under Everything

Market Strength Is Putting Bids Under Everything

The indices are hitting highs as the market shrugs off yesterday's rotation.

10 Biotech Stocks Investors Should Put on Their Shopping List for 2018

10 Biotech Stocks Investors Should Put on Their Shopping List for 2018

Biotech M&A activity will pick up markedly in 2018, and these companies are likely to be the most active in that space.

10 Biotech Stocks to Watch in 2018

10 Biotech Stocks to Watch in 2018

There are a variety of players that should be active in the M&A space next year.

Sarepta Therapeutics Is on Track for Further Gains

Sarepta Therapeutics Is on Track for Further Gains

Look for an increase to the low $60s followed by the $75 area longer term.

How to Play This Cooling Momentum

How to Play This Cooling Momentum

We have shifted from a market that was mainly index driven by the FAANG names to one where stock picking is more important.

Seeing Red and Considering Hedges

Seeing Red and Considering Hedges

Tightening stops, closely watching momentum stocks and considering index shorts as I get more defensive.

Sarepta Rises as FDA Clears Investigational Drug Application -- Biotech Movers

Sarepta Rises as FDA Clears Investigational Drug Application -- Biotech Movers

The Cambridge, Mass.-based firm said Nov. 7 that the U.S. Food and Drug Administration has cleared the investigational new drug application for its peptide phosphorodiamidate morpholino oligomer (PPMO) exon 51 candidate, SRP-5051.

Call a Market Top, Go Ahead, I Dare You

Call a Market Top, Go Ahead, I Dare You

Market's at a high, and so is anxiety.

Who Benefits From Tax Reform?

Who Benefits From Tax Reform?

Technology and biotech companies seem to be among the big winners.

Market Action Isn't So Hot Despite What You May Hear

Market Action Isn't So Hot Despite What You May Hear

Breadth is positive, but pockets of momentum are very limited.

Stocks on My Radar on This Selling

Stocks on My Radar on This Selling

I'm always excited about the potential for new trades when we have selling like this.

MacroGenics Soars on Collaboration with Incyte -- Biotech Movers

MacroGenics Soars on Collaboration with Incyte -- Biotech Movers

MacroGenics and Incyte on Wednesday unveiled a collaboration and license agreement regarding MGA012, MacroGenics' investigational monoclonal antibody that inhibits programmed cell death protein 1.

Market Still Lacks Ability to Find Volatility

Market Still Lacks Ability to Find Volatility

Indices keep hitting highs, yet volatility stays low.

I'm Rooting for an Ugly Close but Not Holding My Breath

I'm Rooting for an Ugly Close but Not Holding My Breath

It would be a welcome change for those of those traders who would like to see increased volatility.

Keep a Close Watch on What the Dip Buyers Do

Keep a Close Watch on What the Dip Buyers Do

When the dip buyers disappear intraday, then the action finally can shift.

Shark Bites: Market Starts Selling the News Even Before Trump Talks Taxes

Shark Bites: Market Starts Selling the News Even Before Trump Talks Taxes

Proposals are having an effect ahead of afternoon announcement.

Sarepta Therapeutics Chart Patterns Look Good

Sarepta Therapeutics Chart Patterns Look Good

Things have been looking better since January.

Watch the Key Technical Levels

Watch the Key Technical Levels

If they are breached, that will trigger more aggressive selling.

Net Seller, but Itching to Put More Cash to Work

Net Seller, but Itching to Put More Cash to Work

This is pretty typical Fed Day action, when traders do some quick trades while they wait.

Biotech Needs a Shot in the Arm

Biotech Needs a Shot in the Arm

But there is hope, as the FDA has approved almost as many new compounds in 2017 as in all of 2016.

Biotech Needs a Shot in the Arm

Biotech Needs a Shot in the Arm

But there is hope, as the FDA has approved almost as many new compounds in 2017 as in all of 2016.

Liking the Look of Some of These Pullbacks

Liking the Look of Some of These Pullbacks

This corrective action has me feeling optimistic about some new opportunities.

Under the Surface, There Are Warnings in This Market

Under the Surface, There Are Warnings in This Market

Small caps are down 0.12% despite the strength in the Nasdaq ETF.

Sarepta CEO Leaves Along With a Sanofi Director, So Let's Speculate About a Possible Deal

Sarepta CEO Leaves Along With a Sanofi Director, So Let's Speculate About a Possible Deal

Sarepta CEO Ed Kaye said he's stepping down.

It's Tough to Figure Out Where to Jump In

It's Tough to Figure Out Where to Jump In

If you aren't positioned long already, you are struggling with what to do here.

My Game Plan Is to Not Trust That Upside

My Game Plan Is to Not Trust That Upside

There has been enough technical damage done lately.

Shark Bites: You Don't Want to Play the Gambler Today

Shark Bites: You Don't Want to Play the Gambler Today

This is one of those days when it may pay to walk away.

Market Is Home on the Range Again

Market Is Home on the Range Again

Emotion of yesterday's collapse is pretty much gone.

Shark Bites: Market Needs a Bounce in Its Step

Shark Bites: Market Needs a Bounce in Its Step

Biotechnology continues to be a bright spot.